Quick Answer
Arcturus Therapeutics Holdings Inc. reported Net Income Loss of -$65.78 million for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +18.7% in Net Income Loss from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$9.95 million | Q3 2018: -$4.25 million | Q1 2019: -$6.88 million | Q2 2019: -$685.0 thousand | Q3 2019: -$7.43 million | Q4 2019: -$10.99 million | Q1 2020: -$9.78 million | Q2 2020: -$10.26 million | Q3 2020: -$21.00 million | Q4 2020: -$31.10 million | Q1 2021: -$56.35 million | Q2 2021: -$54.58 million | Q3 2021: -$54.08 million | Q4 2021: -$38.66 million | Q1 2022: -$51.17 million | Q2 2022: -$21.56 million | Q3 2022: -$35.27 million | Q1 2023: $50.75 million | Q2 2023: -$52.55 million | Q3 2023: -$16.22 million | Q1 2024: -$26.82 million | Q2 2024: -$17.22 million | Q3 2024: -$6.90 million | Q1 2025: -$14.08 million | Q2 2025: -$9.18 million | Q3 2025: -$13.45 million.
- Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Net Income Loss has declined by 202.0%.
- Historical annual values: Fiscal year 2025: -$65.78 million | Fiscal year 2024: -$80.94 million | Fiscal year 2023: -$29.73 million | Fiscal year 2022: $9.35 million | Fiscal year 2021: -$203.67 million | Fiscal year 2020: -$72.15 million | Fiscal year 2019: -$25.99 million | Fiscal year 2018: -$21.79 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: